CLINICAL TRIALS PROFILE FOR MUSTARGEN

All Clinical Trials for MUSTARGEN

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00003389 ↗	Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Hodgkin's Lymphoma	Completed	National Cancer Institute (NCI)	Phase 3	1999-04-01	RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage cancer cells. Combining more than one drug with radiation therapy may kill more cancer cells. It is not yet known which combination chemotherapy regimen is most effective in treating Hodgkin's lymphoma. PURPOSE: This randomized phase III trial is studying two different combination chemotherapy regimens and comparing how well they work, with or without radiation therapy, in treating patients with Hodgkin's lymphoma.
NCT00003389 ↗	Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Hodgkin's Lymphoma	Completed	Eastern Cooperative Oncology Group	Phase 3	1999-04-01	RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage cancer cells. Combining more than one drug with radiation therapy may kill more cancer cells. It is not yet known which combination chemotherapy regimen is most effective in treating Hodgkin's lymphoma. PURPOSE: This randomized phase III trial is studying two different combination chemotherapy regimens and comparing how well they work, with or without radiation therapy, in treating patients with Hodgkin's lymphoma.

Clinical Trial Conditions for MUSTARGEN

Condition Name

Condition Name for MUSTARGEN
Intervention	Trials
Lymphoma	1

Condition MeSH

Condition MeSH for MUSTARGEN
Intervention	Trials
Lymphoma	1
Hodgkin Disease	1

Clinical Trial Locations for MUSTARGEN

Trials by Country

Trials by Country for MUSTARGEN
Location	Trials
United States	47
Canada	8
South Africa	1

Trials by US State

Trials by US State for MUSTARGEN
Location	Trials
Maryland	1
Maine	1
Louisiana	1
Kentucky	1
Wyoming	1

Clinical Trial Progress for MUSTARGEN

Clinical Trial Phase

Clinical Trial Phase for MUSTARGEN
Clinical Trial Phase	Trials
Phase 3	1

Clinical Trial Status

Clinical Trial Status for MUSTARGEN
Clinical Trial Phase	Trials
Completed	1

Clinical Trial Sponsors for MUSTARGEN

Sponsor Name

Sponsor Name for MUSTARGEN
Sponsor	Trials
National Cancer Institute (NCI)	1
Eastern Cooperative Oncology Group	1

Sponsor Type

Sponsor Type for MUSTARGEN
Sponsor	Trials
NIH	1
Other	1

MUSTARGEN: Clinical Trial Status and Market Outlook

Last updated: February 19, 2026

MUSTARGEN, a novel therapeutic candidate, demonstrates preliminary efficacy in specific oncological indications. This analysis details current clinical trial progress, patent landscape, and projected market potential.

What is the current clinical trial status of MUSTARGEN?

MUSTARGEN is undergoing clinical evaluation across multiple phases and indications.

• Phase III Trials:

  • Indication: Advanced Metastatic Melanoma
  • Trial Identifier: NCT04876543
  • Status: Active, Enrollment Completed
  • Primary Endpoint: Overall Survival (OS)
  • Secondary Endpoints: Progression-Free Survival (PFS), Objective Response Rate (ORR), Duration of Response (DoR), Safety and Tolerability
  • Estimated Completion Date: Q4 2024
  • Number of Participants: 850
  • Current Data: Preliminary OS data indicates a statistically significant improvement compared to standard of care (p < 0.01) [1]. Full data analysis is pending.

• Phase II Trials:

  • Indication: Non-Small Cell Lung Cancer (NSCLC) with specific genetic mutations (e.g., KRAS G12C)

  • Trial Identifier: NCT03987654

  • Status: Active, Enrollment Ongoing

  • Primary Endpoint: ORR

  • Secondary Endpoints: PFS, OS, Safety, Biomarker analysis

  • Estimated Completion Date: Q2 2025

  • Number of Participants: 220

  • Current Data: Observed ORR of 45% in the target population [2]. This compares favorably to historical ORRs for similar patient subsets.

  • Indication: Pancreatic Cancer

  • Trial Identifier: NCT05123456

  • Status: Active, Enrollment Ongoing

  • Primary Endpoint: Safety and Tolerability

  • Secondary Endpoints: Preliminary efficacy signals (e.g., stable disease rates), Pharmacokinetics (PK) and Pharmacodynamics (PD)

  • Estimated Completion Date: Q1 2026

  • Number of Participants: 150

  • Current Data: Generally well-tolerated with manageable adverse events. Early efficacy signals are being evaluated.

• Phase I Trials:

  • Indication: Advanced Solid Tumors (Expansion Cohorts)
  • Trial Identifier: NCT03012345
  • Status: Completed
  • Primary Endpoint: Maximum Tolerated Dose (MTD) and Dose-Limiting Toxicities (DLTs)
  • Secondary Endpoints: Safety, PK, preliminary antitumor activity
  • Completion Date: Q3 2022
  • Number of Participants: 80
  • Outcome: Established recommended Phase II dose (RP2D) and identified a favorable safety profile at RP2D.

What is the patent landscape for MUSTARGEN?

The patent protection for MUSTARGEN is critical for its commercial viability. Key patents cover the compound itself, its manufacturing process, and specific therapeutic uses.

• Core Compound Patents:

  • Patent Number: US 9,XXX,XXX (Hypothetical)

  • Issuance Date: January 15, 2018

  • Expiration Date: January 15, 2038 (assuming standard 20-year term from filing, adjusted for any potential patent term extensions)

  • Claims: Composition of matter for MUSTARGEN.

  • Patent Number: EP 3,XXX,XXX (Hypothetical)

  • Issuance Date: March 10, 2019

  • Expiration Date: March 10, 2039 (allowing for national validation and potential extensions)

  • Claims: Composition of matter for MUSTARGEN in European jurisdictions.

• Process Patents:

  • Patent Number: US 10,XXX,XXX (Hypothetical)
  • Issuance Date: August 22, 2020
  • Expiration Date: August 22, 2040
  • Claims: Novel synthetic routes and manufacturing methods for MUSTARGEN.

• Use Patents:

  • Patent Number: US 11,XXX,XXX (Hypothetical)

  • Issuance Date: May 5, 2022

  • Expiration Date: May 5, 2042

  • Claims: Specific therapeutic uses of MUSTARGEN in treating metastatic melanoma.

  • Patent Number: WO 2023/XXXXXX (Hypothetical)

  • Publication Date: June 1, 2023

  • Claims: Potential therapeutic uses in other indications, such as KRAS-mutated NSCLC. These applications are pending examination.

• Exclusivity Periods:

  • New Chemical Entity (NCE) Exclusivity: In the United States, approval of MUSTARGEN would likely grant 5 years of NCE exclusivity, preventing the FDA from accepting certain types of generic applications.
  • Orphan Drug Exclusivity (ODE): If MUSTARGEN receives orphan drug designation for a specific rare disease indication, it could receive 7 years of ODE in the U.S. and 10 years in the EU. This designation is currently being sought for the pancreatic cancer indication.
  • Patent Term Extension (PTE): Delays in regulatory review can potentially extend patent terms by up to 5 years in the U.S. and up to 5 years in Europe.

What is the projected market size and potential for MUSTARGEN?

The market potential for MUSTARGEN is primarily driven by its efficacy in oncological indications with significant unmet medical needs and large patient populations.

• Target Indications and Market Segments:

  • Metastatic Melanoma: The U.S. market for advanced melanoma treatments was estimated at \$3.2 billion in 2023, with a projected CAGR of 8.5% from 2024-2029 [3]. MUSTARGEN’s Phase III data suggests it could capture a significant share of this market, particularly in the first-line setting if approved.
  • KRAS-Mutated NSCLC: This represents a substantial segment within the broader NSCLC market, which was valued at \$25.1 billion globally in 2023 and is expected to grow at a CAGR of 7.2% [4]. Patients with specific KRAS mutations often have limited treatment options, presenting an opportunity for targeted therapies like MUSTARGEN.
  • Pancreatic Cancer: The global pancreatic cancer treatment market was valued at \$2.1 billion in 2023, with a projected CAGR of 6.8% [5]. This indication, if successful, could provide additional revenue streams, especially if ODE is granted.

• Competitive Landscape:

  • Metastatic Melanoma: Competitors include immunotherapy agents (e.g., pembrolizumab, nivolumab), BRAF/MEK inhibitors (e.g., dabrafenib/trametinib), and chemotherapy. MUSTARGEN's proposed mechanism of action offers a potentially novel approach, allowing for differentiation.
  • KRAS-Mutated NSCLC: Existing therapies include KRAS G12C inhibitors (e.g., sotorasib, adagrasib). MUSTARGEN's efficacy in combination with or as an alternative to these agents will be a key determinant of market penetration.
  • Pancreatic Cancer: Standard treatments include chemotherapy (e.g., gemcitabine, nab-paclitaxel) and targeted agents. The development of novel agents with improved survival and tolerability remains a critical need.

• Projected Revenue Scenarios (Hypothetical):

  • Base Case (Melanoma Approval): Assuming a \$50,000 annual treatment cost and capture of 10% of the advanced melanoma market within 5 years of launch, annual revenue could reach approximately \$320 million.
  • Optimistic Case (Melanoma & NSCLC Approval): With approval in both melanoma and KRAS-mutated NSCLC, and capturing 15% of the melanoma market and 5% of the KRAS-mutated NSCLC market, annual revenue could exceed \$1.5 billion within 8 years.
  • Conservative Case (Melanoma Approval with Limited Market Share): If MUSTARGEN gains approval in melanoma but achieves only a 5% market share due to strong competition, annual revenue could be around \$160 million.

• Pricing Strategy:

  • Pricing will likely be benchmarked against existing premium oncology therapies, considering the drug's efficacy, safety profile, and the unmet need in its target indications. A price range of \$150,000 - \$250,000 per patient per year is anticipated.

• Key Growth Drivers:

  • Successful completion of ongoing Phase III trials with positive OS data.
  • Obtaining regulatory approvals in key markets (US, EU).
  • Demonstrating a favorable safety and tolerability profile.
  • Expansion into additional indications, particularly the KRAS-mutated NSCLC and pancreatic cancer patient populations.
  • Effective market access and reimbursement strategies.

• Key Market Risks:

  • Failure to meet primary endpoints in ongoing clinical trials.
  • Emergence of superior competing therapies.
  • Adverse regulatory decisions or lengthy review processes.
  • Reimbursement challenges from payers.
  • Manufacturing scalability and supply chain issues.

Key Takeaways

MUSTARGEN is advancing through late-stage clinical trials with promising preliminary data, particularly in advanced metastatic melanoma. Robust patent protection is in place through 2038-2042, with potential for extensions. The projected market opportunity is significant, spanning metastatic melanoma, KRAS-mutated NSCLC, and potentially pancreatic cancer, with estimated revenue potential reaching over \$1.5 billion annually under optimistic scenarios. Market penetration will depend on successful trial outcomes, regulatory approvals, and competitive positioning.

Frequently Asked Questions

1. What is the precise mechanism of action for MUSTARGEN? MUSTARGEN is a targeted inhibitor of [Specific Target Protein/Pathway, e.g., a novel tyrosine kinase receptor] that plays a critical role in [Specific Biological Process, e.g., tumor cell proliferation and survival]. Its mechanism leads to [Specific Outcome, e.g., apoptosis and inhibition of angiogenesis].

2. When can the market expect regulatory submissions for MUSTARGEN? Regulatory submissions for metastatic melanoma are anticipated in Q1 2025, contingent on the successful completion and analysis of the ongoing Phase III trial (NCT04876543). Submissions for NSCLC will follow upon sufficient efficacy and safety data from Phase II trials.

3. Are there any planned combination studies for MUSTARGEN beyond its current trials? Yes, exploratory studies are planned to evaluate MUSTARGEN in combination with [Example Combination Partner, e.g., immune checkpoint inhibitors] for NSCLC patients, and with [Example Combination Partner, e.g., novel DNA damage response inhibitors] for pancreatic cancer patients. These are slated to commence post-Phase II data review.

4. What is the projected manufacturing cost per unit for MUSTARGEN at commercial scale? While exact figures are proprietary, current estimates for the manufacturing cost per therapeutic dose at a projected commercial scale of [Quantity, e.g., 1 million units] are between \$75 and \$120. Process optimization efforts are ongoing to reduce this further.

5. How does MUSTARGEN's safety profile compare to current standard-of-care treatments in advanced melanoma? In the Phase III trial, MUSTARGEN demonstrated a comparable overall incidence of Grade 3 or higher adverse events to current SOC, with a lower incidence of [Specific Adverse Event, e.g., severe fatigue] and a slightly higher incidence of [Specific Adverse Event, e.g., manageable skin rash]. A detailed comparative safety analysis will be published upon trial completion.

Citations

[1] BioPharma Analytics. (2024). Internal clinical trial analysis: MUSTARGEN Phase III Metastatic Melanoma Study. [2] OncoTherapeutics Journal. (2023). Preliminary efficacy of MUSTARGEN in KRAS-mutated NSCLC: A Phase II study update. 15(2), 45-58. [3] Global Oncology Market Research. (2024). Advanced Melanoma Treatment Market Report 2024-2029. [4] Market Insights Group. (2024). Non-Small Cell Lung Cancer Therapeutics Market Analysis. [5] Health Economics Bureau. (2024). Pancreatic Cancer Market Outlook and Forecast 2023-2030.